There is only one week left to take advantage of ILC 2021 early fees! The deadline is Monday, 22 March 23:59 CET. Don't wait for the last minute to save up to EUR 450. Browse the categories to find out what…
EASL’s ILC 2021 will be the 56th iteration of a flagship annual congress – a firmly rooted tradition that is set to be a sparkling, four-day virtual event taking place 23–26 June 2021. Over half a century has passed since the first EASL meeting took place in 1966…
At EASL, we are pleased to support the relaunch of the international reporting registry COVID-Hep 2.0. Accordingly, EASL encourages healthcare professionals to share the registry among its networks. Every individual and centre that submits at least one case will be…
Are you deeply engaged in hepatology and science and ready to get involved in EASL’s governance? EASL is now looking to fill the following positions: EASL Vice-Secretary Three Educational Committee Members Three Policy and Public Health Committee Members Three Young Investigators Task Force Members…
EASL honours Rare Disease Day, taking place this Sunday, 28 February. An estimated 300 million people globally are affected by rare diseases – diseases of which 6,000 have been identified.
In the wake of the COVID-19 pandemic, several liver associations recommended certain changes in hepatitis clinical care to mitigate transmission risks for severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), the causative agent of COVID-19. A follow-up survey was conducted and…
On International Day of Women and Girls in Science, 11 February, EASL honours the many women making waves in our field of hepatology. As highlighted by the UN, both science and gender equality are vital for us to achieve the…
9 February 2021 By end-January 2021, COVID-19, the systemic disease caused by the pandemic spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), accounted for 2.2 million deaths worldwide and for 100 million individuals infected, according to estimates from the…
Digital Liver Cancer Summit 2021: New follow-up data from a landmark study of liver cancer patients treated with a combination of atezolizumab and bevacizumab has shown the longest ever survival time in a frontline phase 3 trial of systemic therapy…
Digital Liver Cancer Summit 2021: A global survey assessing the impact of COVID-19 on liver cancer has revealed delays in the screening, diagnosis, and treatment of the disease, with experts issuing stark warnings on liver cancer survival rates. February 5,…